Author summary Why was this study done? Clinical trials are the foundation of evidence-based medicine and should follow established guidelines for transparency: Their results should be available, findable, and accessible regardless of the outcome. Previous studies have shown that many clinical trials fall short of transparency guidelines, which distorts the medical evidence base, creates research waste, and undermines medical decision-making. University Medical Centers (UMCs) play an important role in increasing clinical trial transparency but are often unaware of their performance on these practices, making it difficult to drive improvement. What did the researchers do and find? We developed a pipeline to evaluate clinical trials across several established practices for clinical trial transparency and applied it in a cohort of 2,895 clinical trials led by German UMCs. We found that while some practices are gaining adherence (e.g., prospective registration in ClinicalTrials.gov increased from 33% to 75% over the period considered), there is much room for improvement (e.g., 41% of trials reported results within 2 years of trial completion). We developed a dashboard to communicate these transparency assessments to UMCs and support their efforts to improve. What do these findings mean? Our study demonstrates the feasibility of developing a dashboard to communicate adherence to established practices for clinical trial transparency. By highlighting areas for improvement, the dashboard provides actionable information to UMCs and empowers their efforts to improve. The dashboard may inform interventions to increase clinical trial transparency and be scaled to other countries and stakeholders, such as funders or clinical trial registries.